382129
HIV Reverse Transcriptase, Recombinant, E. coli
liquid, ≥5,000 units/mg protein, Nuclease-free
Synonym(s):
HIV RT
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352202
Recommended Products
recombinant
expressed in E. coli
Quality Level
form
liquid
specific activity
≥10,000 units/mL
≥5,000 units/mg protein
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
technique(s)
molecular cloning: suitable
foreign activity
Nuclease-free
shipped in
wet ice
storage temp.
−20°C
General description
Recombinant HIV reverse transcriptase expressed in E. coli. Catalyzes error-prone synthesis on DNA and RNA templates. Provides an excellent target for evaluating antiviral agents.
Application
HIV Reverse Transcriptase, Recombinant, E.coli has been used as a standard in reverse transcriptase activity assay.
Packaging
Please refer to vial label for lot-specific concentration.
Warning
Toxicity: Standard Handling (A)
Unit Definition
One unit is defined as the amount of enzyme that will incorporate 1.0 nmol of labeled dTTP into acid-insoluble material in 20 min at 37°C, pH 8.3.
Physical form
In 10 mM potassium phosphate, 1 mM DTT, 20% glycerol, pH 7.4.
Reconstitution
Following initial thaw, aliquot and freeze (-20°C).
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
10 - Combustible liquids
WGK
WGK 1
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Geraldine Vilmen et al.
mBio, e0275221-e0275221 (2022-01-12)
Infection of rhesus macaques with simian-human immunodeficiency viruses (SHIVs) is the preferred model system for vaccine development because SHIVs encode human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins (Envs)-a key target of HIV-1 neutralizing antibodies. Since the goal of vaccines
Jonathan C Reed et al.
Journal of virology, 95(3) (2020-11-06)
Given the projected increase in multidrug-resistant HIV-1, there is an urgent need for development of antiretrovirals that act on virus life cycle stages not targeted by drugs currently in use. Host-targeting compounds are of particular interest because they can offer
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service